Biobot Analytics
Biobot Analytics, founded in 2017 by Mariana Matus and Newsha Ghaeli, emerged from research conducted at MIT in 2014.
Profile
Biobot Analytics provides real-time health intelligence by analyzing wastewater for pathogens and substances.
Biobot Analytics, founded in 2017 by Mariana Matus and Newsha Ghaeli, emerged from research conducted at MIT in 2014. Initially focused on tracking opioids in wastewater, the company pivoted to monitoring infectious diseases during the COVID-19 pandemic, becoming a leader in wastewater epidemiology. Biobot’s platform provides real-time data on pathogens like SARS-CoV-2, influenza, and RSV, as well as substances such as fentanyl and cocaine, offering insights for public health departments and policymakers.
The company has raised $42.7 million over five funding rounds, with notable investors including Valor Equity Partners and Y Combinator. Biobot’s customer base spans municipalities, universities, and healthcare organizations, leveraging its data to anticipate health trends and inform decisions. Recent developments include the launch of a respiratory illnesses panel and securing funding for nationwide wastewater-based monitoring programs. Despite its growth, Biobot faces challenges such as competition in the wastewater analytics space and the need to continuously validate its data’s accuracy and relevance.
Who buys this
- Municipalities and local governments
- Universities and educational institutions
- Healthcare organizations
- Public health departments
- Research institutions
Strengths and what to watch
Strengths
- First mover advantage in wastewater-based epidemiology
- Comprehensive monitoring of pathogens and substances
- Strong partnerships with public health organizations
Watch for
- Increasing competition in the wastewater analytics market
- Dependence on government and institutional funding
- Potential challenges in scaling data validation processes
Key Information
- Founded
- 2017
- Employees
- 28
- Country
- United States
Frequently Asked Questions
What is wastewater epidemiology and how does it work?
Wastewater epidemiology analyzes sewage to detect pathogens and substances, providing real-time public health data. Biobot Analytics tests wastewater for viruses like COVID-19, influenza, and RSV, plus substances including opioids. This helps track community health trends without individual testing, offering early outbreak warnings.
What does Biobot Analytics do?
Biobot Analytics monitors public health by testing wastewater for pathogens and drugs. Founded in 2017, it pivoted from opioid tracking to infectious disease monitoring during COVID-19. Their platform provides data on viruses and substances to governments, universities, and health organizations for decision-making.
Who uses Biobot Analytics' data?
Biobot serves municipalities, universities, healthcare groups, and public health departments. Their wastewater data helps these organizations track disease spread, monitor substance use, and allocate resources. Customers rely on Biobot for real-time insights to anticipate health trends and inform policy.
How is Biobot Analytics funded?
Biobot has raised $42.7 million across five funding rounds. Investors include Valor Equity Partners and Y Combinator. This funding supports their wastewater monitoring technology and expansion, including recent respiratory illness panels and nationwide programs.
What are Biobot Analytics' main competitors?
Biobot faces growing competition in wastewater analytics, though specifics aren't detailed. Challenges include maintaining data accuracy as they scale and differentiating their comprehensive pathogen and substance monitoring. Their first-mover advantage and public health partnerships remain key strengths.
How did Biobot Analytics pivot during COVID-19?
Originally focused on opioid detection, Biobot shifted to infectious disease tracking when the pandemic hit. Leveraging MIT research, they became leaders in monitoring SARS-CoV-2 in wastewater. This pivot positioned them as vital for real-time pandemic response data.
Sources
- biobot.io — Biobot’s real-time data insights for COVID-19, influenza, and RSV
- tracxn.com — Biobot’s funding rounds and investors
- biobot.io — Launch of Biobot’s Respiratory Illnesses Panel
- www.cambridgeday.com — Biobot’s origins and pivot during the COVID-19 pandemic